FDA Accepts New Drug Application for Acorda’s Parkinson’s Therapy Inbrija

FDA Accepts New Drug Application for Acorda’s Parkinson’s Therapy Inbrija
The U.S. Food and Drug Administration has accepted Acorda Therapeutics’ New Drug Application for Inbrija (CVT-301) as a potential treatment for Parkinson’s disease. Accepting the application means the agency is ready to start its regulatory review of the therapy. It expects to make a decision by Oct. 5, 2018. Inbrija is an inhaled powder formulation of levodopa for the times when ... read more
Source: Parkinson’s News TodayPublished on 2018-02-23By Jose Marques Lopes, PhD